Nevertheless,
Trump: he threatens novartis roche:
Customs duties
Trump launches an ultimatum in Novartis. For example, Roche
In a letter addressed to the giants Novartis and Roche, the American president demands a drop in prices for American citizens
For Donald Trump, the price of drugs is an “unacceptable burden”
KEYSTONE
In a letter addressed to the boss of Novartis Visant Narasimhan. Meanwhile, Donald Trump strongly criticized the high prices of brand medicines in the United States. For example, These would be up to three times more expensive than in other countries-for identical products. Moreover, Trump describes this as “unacceptable trump: he threatens novartis roche burden” for American families and announces that he wants to end it.
For the future. In addition, it requires pharmaceutical companies a clear commitment: all drugs must be offered in the United States only at the lowest international price. Meanwhile, American families must be relieved immediately. Therefore, Trump fixes a delay on September 29 for a response from Novartis.
The threats are clear: if companies refuse. In addition, its government “will use all means” to protect the population against “an abusive price policy”. Pharmaceutical companies have been enriched too long at the expense of American innovation and must now pay “their fair share”.
Letters to other pharmas
In total, Trump sent similar requests to 17 other pharmaceutical companies such as Pfizer, Sanofi, Merck and Astrazeneca. Roche. the second large trump: he threatens novartis roche pharmaceutical group, also received this letter, addressed to Ashley Magargee, the director of Genentech, the American subsidiary of the group.
However, Novartis announced in April investments of $ 23 billion in the United States to score points with the American president. This money must be invested over five years in ten research and production sites in the United States.
Roche will invest $ 50 billion in the next five years in new production facilities. research sites or enlarged in American territory.
While drug prices are now under pressure in the United States, Novartis is asking for higher prices in Europe. Its director general recently described this situation in these terms: “We are convinced that Europe must improve in its. ability to reward innovative drugs”.
A lucrative market with a trump: he threatens novartis roche risk of concentration
While drug prices are highly regulated in Europe. operation is different in the United States. In principle, the government has little influence on drug prices, which is why they are significantly higher than elsewhere. Roche and Novartis each realize about half of their turnover in the United States.
During his first mandate. Trump had already tried, without success, to link medication reimbursement prices to the lowest prices in countries rich in comparison-which was to lower prices in the United States. The proposal has never been implemented, due to the legal and political opposition.
It is still unknown how the best price guarantee for new drugs will work. A journalist from the American channel CNBC pointed out that the pricing “Most Favored Nation” – the guarantee of. the best price trump: he threatens novartis roche – is based on the prices practiced abroad. The problem is that new drugs are generally introduced first into the American market. so there is no possibility of comparison for lower prices.
“Latest news”
Do you want to stay at the top of the info? “24 hours” offers you two meetings a day. not to miss anything of what is happening in your canton, in Switzerland or in the world.
Other newsletters
Did you find an error? Please report it to us.
Further reading: Does Jeff Bezos want to buy Vogue as a wedding gift for his wife? – Colaabor victim of an important computer attack – The Relais saturated Relais terminals in Angoulême: why you can no longer put your clothes there – The smart investor: it’s still fun, beat the clues! – from Openai to Meta and Google, driven of fever in AI.
